Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of 2mg/day of M100907 [volinanserin] on sleep maintenance insomnia with a sub-study of the effect of M100907 on stable type II diabetes mellitus: a one year, multi-center, randomized, double-blind, placebo-controlled study

Next Previous
Search
Trial Profile

Efficacy and safety of 2mg/day of M100907 [volinanserin] on sleep maintenance insomnia with a sub-study of the effect of M100907 on stable type II diabetes mellitus: a one year, multi-center, randomized, double-blind, placebo-controlled study

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Volinanserin (Primary)
  • Indications Sleep maintenance insomnia
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms SAMS
  • Sponsors Sanofi

Most Recent Events

  • 19 Jan 2022 This trial has been completed in Greece (End Date: 1 Mar 2009), according to European Clinical Trials Database record.
  • 01 Sep 2009 Actual patient number (1847) added as reported by ClinicalTrials.gov.
  • 01 Mar 2009 Status changed from recruiting to discontinued, as reported by clinicaltrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top